Literature DB >> 1391968

Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization.

K Inoue1, J Inazawa, H Nakagawa, T Shimada, H Yamazaki, F P Guengerich, T Abe.   

Abstract

We have used a full length cDNA clone (2.2 kb) for the human cytochrome P-450 nifedipine oxidase (CYP3A4) enzyme as a probe to determine its chromosome localization by fluorescence in situ hybridization. CYP3A4 was mapped on R-banded human prometaphase chromosomes, and the precise localization of CYP3A4 on chromosome 7 was further confirmed by a delineation of G-banded pattern on the same prometaphase chromosomes through a combination of UV-filter. We assigned CYP3A4 to chromosome 7 at q22.1.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1391968     DOI： 10.1007/BF01899734

Source DB:  PubMed          Journal:  Jpn J Hum Genet        ISSN： 0916-8478


  10 in total

Review 1.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 2.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

4.  Polymorphism of CYP3A4 2 and eNOS genes in the diabetic patients with hyperlipidemia undergoing statin treatment.

Authors:  Kaiser Jamil; Vidya Kandula; Ramoji Kandula; M Asimuddin; Sindu Joshi; Shiva Kumar Yerra
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

5.  Association of CYP3A4 genotype with treatment-related leukemia.

Authors:  C A Felix; A H Walker; B J Lange; T M Williams; N J Winick; N K Cheung; B D Lovett; P C Nowell; I A Blair; T R Rebbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 6.  Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.

Authors:  Ibrahim Ince; Catherijne A J Knibbe; Meindert Danhof; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

Review 7.  CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis.

Authors:  Li-Ping Zhou; Fan Yao; Hong Luan; Yin-Ling Wang; Xi-Hua Dong; Wen-Wen Zhou; Qi-Hui Wang
Journal:  Tumour Biol       Date:  2012-11-20

8.  Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients.

Authors:  Abdulkareem Albekairy; Abdulmalik Alkatheri; Shiro Fujita; Alan Hemming; Richard Howard; Alan Reed; Janet Karlix
Journal:  Saudi J Gastroenterol       Date:  2013 Mar-Apr       Impact factor: 2.485

9.  Chromosomal assignment of the gene for protein tyrosine phosphatase HPTP delta.

Authors:  K Hasegawa; T Ariyama; J Inazawa; K Mizuno; M Ogimoto; T Katagiri; H Yakura
Journal:  Jpn J Cancer Res       Date:  1993-12

10.  Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.

Authors:  Miriam Saiz-Rodríguez; Susana Almenara; Marcos Navares-Gómez; Dolores Ochoa; Manuel Román; Pablo Zubiaur; Dora Koller; María Santos; Gina Mejía; Alberto M Borobia; Cristina Rodríguez-Antona; Francisco Abad-Santos
Journal:  Biomedicines       Date:  2020-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.